Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

2.

RNAi-mediated gene silencing in non-human primates.

Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I.

Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.

PMID:
16565705
3.

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM.

J Control Release. 2012 May 10;159(3):384-92. doi: 10.1016/j.jconrel.2012.01.045. Epub 2012 Feb 8.

4.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21. Epub 2007 Mar 22.

5.

RNA interference: Homing in on delivery.

Baker M.

Nature. 2010 Apr 22;464(7292):1225-8. doi: 10.1038/4641225a. No abstract available.

PMID:
20414308
6.

Targeted delivery systems of small interfering RNA by systemic administration.

Kawakami S, Hashida M.

Drug Metab Pharmacokinet. 2007 Jun;22(3):142-51. Review.

7.

Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo.

Choi KM, Kim K, Kwon IC, Kim IS, Ahn HJ.

Mol Pharm. 2013 Jan 7;10(1):18-25. doi: 10.1021/mp300211a. Epub 2012 Jun 12.

PMID:
22663765
8.

Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.

Gao J, Chen H, Yu Y, Song J, Song H, Su X, Li W, Tong X, Qian W, Wang H, Dai J, Guo Y.

Biomaterials. 2013 Dec;34(38):10084-98. doi: 10.1016/j.biomaterials.2013.08.088. Epub 2013 Sep 20.

PMID:
24060417
9.

Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.

Zhang M, Wang J, Yao R, Wang L.

Int J Gynecol Cancer. 2013 May;23(4):659-66. doi: 10.1097/IGC.0b013e318287e2b3.

PMID:
23466567
10.
12.

RNA interference: From tools to therapies.

Baker M.

Nature. 2010 Apr 22;464(7292):1225. doi: 10.1038/4641225b. No abstract available.

PMID:
20414309
13.

Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines.

Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N.

Nat Mater. 2010 Nov;9(11):923-8. doi: 10.1038/nmat2859. Epub 2010 Oct 10.

14.

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP.

Nature. 2004 Nov 11;432(7014):173-8.

15.

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd.

Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28.

16.

Nanoparticle-based delivery system for application of siRNA in vivo.

Wang Y, Li Z, Han Y, Liang LH, Ji A.

Curr Drug Metab. 2010 Feb;11(2):182-96. Review.

PMID:
20359287
17.

Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.

Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A.

Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. doi: 10.1016/j.ejpb.2010.11.007. Epub 2010 Nov 18. Review.

PMID:
21093588
18.

Therapeutic siRNA: principles, challenges, and strategies.

Gavrilov K, Saltzman WM.

Yale J Biol Med. 2012 Jun;85(2):187-200. Epub 2012 Jun 25. Review.

19.

Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.

Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, Huang L.

Mol Ther. 2013 Oct;21(10):1919-29. doi: 10.1038/mt.2013.135. Epub 2013 Jun 18.

20.

Systemic delivery of small RNA using lipid nanoparticles.

Asai T, Oku N.

Biol Pharm Bull. 2014;37(2):201-5. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk